We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Horizon (HZNP) Q1 Earnings and Revenues Miss Estimates
Read MoreHide Full Article
Horizon Therapeutics plc reported first-quarter 2023 adjusted earnings of 83 cents per share, which missed the Zacks Consensus Estimate of $1.17. The company reported adjusted earnings of $1.34 per share in the year-ago quarter.
Quarterly revenues of $832 million declined 6% year over year, owing mostly to the seasonal impact on Tepezza sales, which the company typically sees with its infused medicines in the first quarter of each year. Revenues fell short of the Zacks Consensus Estimate of $896 million.
Shares of Horizon have rallied 16.8% in the past year against the industry’s 9.1% fall.
Image Source: Zacks Investment Research
Quarter in Detail
Horizon reported financial results in the single segment, owing to the wind-down of the inflammation business, beginning in the fourth quarter of 2022.
In the unified segment, Tepezza sales construed 48.7% of the net sales amounting to $405.3 million, which missed the Zacks Consensus Estimate of $493 million. Per management, the field-force expansion initiated late in 2022 has not yet substantially impacted net sales.
Krystexxa sales rose 33% year over year to $187 million.
Ravicti sales were $90.3 million in the quarter, up 15% year over year.
Procysbi sales were $50.5 million in the quarter, up 2% year over year.
Uplizna sales were $53.8 million in the quarter, up 77% year over year.
Actimmune sales were $29.1 million in the quarter, down 7% year over year.
Research and development expenses were $134.1 million, up 30% from the year-ago quarter. Selling, general and administrative expenses were $453.4 million, up 21.6% from the year-ago quarter.
The company had cash, cash equivalents and investments worth $2.31 billion as of Mar 31, 2023, compared with $2.35 billion as of Dec 31, 2022.
Recent Updates
We would like to remind the investors that Amgen (AMGN - Free Report) is set to acquire Horizon for $116.5 per share in cash or $27.8 billion.
The acquisition was announced in December 2022. This acquisition will add Horizon’s portfolio of rare disease drugs like Tepezza, Krystexxa and Uplizna to Amgen’s broad and diversified portfolio.
Horizon Therapeutics Public Limited Company Price and EPS Surprise
In the past 90 days, the Zacks Consensus Estimate for Aptinyx’s 2023 loss per share has narrowed from 77 cents to 47 cents. In the past year, shares of Aptinyx have fallen by 86.5%.
APTX beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 6.56%.
In the past 90 days, the consensus estimate for ADMA Biologics’ 2023 loss per share has narrowed from 19 cents to 14 cents. In the past year, shares of ADMA Biologics have increased by 66.6%.
ADMA beat estimates in three out of the trailing four quarters, missing the mark on one occasion, delivering an average earnings surprise of 2.88%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Horizon (HZNP) Q1 Earnings and Revenues Miss Estimates
Horizon Therapeutics plc reported first-quarter 2023 adjusted earnings of 83 cents per share, which missed the Zacks Consensus Estimate of $1.17. The company reported adjusted earnings of $1.34 per share in the year-ago quarter.
Quarterly revenues of $832 million declined 6% year over year, owing mostly to the seasonal impact on Tepezza sales, which the company typically sees with its infused medicines in the first quarter of each year. Revenues fell short of the Zacks Consensus Estimate of $896 million.
Shares of Horizon have rallied 16.8% in the past year against the industry’s 9.1% fall.
Image Source: Zacks Investment Research
Quarter in Detail
Horizon reported financial results in the single segment, owing to the wind-down of the inflammation business, beginning in the fourth quarter of 2022.
In the unified segment, Tepezza sales construed 48.7% of the net sales amounting to $405.3 million, which missed the Zacks Consensus Estimate of $493 million. Per management, the field-force expansion initiated late in 2022 has not yet substantially impacted net sales.
Krystexxa sales rose 33% year over year to $187 million.
Ravicti sales were $90.3 million in the quarter, up 15% year over year.
Procysbi sales were $50.5 million in the quarter, up 2% year over year.
Uplizna sales were $53.8 million in the quarter, up 77% year over year.
Actimmune sales were $29.1 million in the quarter, down 7% year over year.
Research and development expenses were $134.1 million, up 30% from the year-ago quarter. Selling, general and administrative expenses were $453.4 million, up 21.6% from the year-ago quarter.
The company had cash, cash equivalents and investments worth $2.31 billion as of Mar 31, 2023, compared with $2.35 billion as of Dec 31, 2022.
Recent Updates
We would like to remind the investors that Amgen (AMGN - Free Report) is set to acquire Horizon for $116.5 per share in cash or $27.8 billion.
The acquisition was announced in December 2022. This acquisition will add Horizon’s portfolio of rare disease drugs like Tepezza, Krystexxa and Uplizna to Amgen’s broad and diversified portfolio.
Horizon Therapeutics Public Limited Company Price and EPS Surprise
Horizon Therapeutics Public Limited Company price-eps-surprise | Horizon Therapeutics Public Limited Company Quote
Zacks Rank and Stocks to Consider
Horizon currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Aptinyx and ADMA Biologics (ADMA - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate for Aptinyx’s 2023 loss per share has narrowed from 77 cents to 47 cents. In the past year, shares of Aptinyx have fallen by 86.5%.
APTX beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 6.56%.
In the past 90 days, the consensus estimate for ADMA Biologics’ 2023 loss per share has narrowed from 19 cents to 14 cents. In the past year, shares of ADMA Biologics have increased by 66.6%.
ADMA beat estimates in three out of the trailing four quarters, missing the mark on one occasion, delivering an average earnings surprise of 2.88%.